All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Isatuximab-irfc,Pomalidomide,Dexamethasone
Therapeutic Area: Oncology Product Name: Sarclisa
Highest Development Status: Approved Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 16, 2020
Details:
Sarclisa (isatuximab) has been recommended in combination with pomalidomide and dexamethasone (pom-dex) for adult with relapsed/refractory multiple myeloma who have received three prior lines of treatment, and at least two prior therapies including lenalidomide and a proteasome inhibitor.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Isatuximab,Pomalidomide,Dexamethasone
Therapeutic Area: Oncology Product Name: Sarclisa
Highest Development Status: Approved Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 08, 2020
Details:
SARCLISA™ in combination with pom-dex significantly reduced the risk of disease progression or death by 40% compared to pom-dex alone in a pivotal trial.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Isatuximab,Pomalidomide,Dexamethasone
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Approved Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 02, 2020
Details:
EC approval based on data from first randomized Phase 3 trial (ICARIA-MM) to report results evaluating an anti-CD38 monoclonal antibody combined with pomalidomide and dexamethasone (pom-dex).
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Isatuximab,Pomalidomide,Dexamethasone
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Approved Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 27, 2020
Details:
Positive CHMP opinion based on data from ICARIA-MM, the first randomized Phase 3 trial to evaluate an anti-CD38 in combination with pom-dex.
Lead Product(s): Encorafenib,Cetuximab
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 01, 2020
Details:
Phase 3 BEACON CRC trial data showed that BRAFTOVI in combination with cetuximab significantly improved overall survival in patients with BRAFV600E-mutant mCRC and reduced the risk of death by 40%.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Dinutuximab
Therapeutic Area: Oncology Product Name: Qarziba
Highest Development Status: Approved Product Type: Large molecule
Partner/Sponsor/Collaborator: BeiGene
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 09, 2020
Details:
QARZIBA® is a monoclonal antibody that is specifically directed against the carbohydrate moiety of disialoganglioside 2 (GD2), which is overexpressed on neuroblastoma cells.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Belinostat
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Acrotech Biopharma
Deal Size: $6.6 million Upfront Cash: $6.6 million
Deal Type: Agreement April 06, 2020
Details:
The new Agreement grants Acrotech a royalty-free license to belinostat in all other territories including the United States, Canada, Mexico, and India.
Drugs in Development
Market Place
Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace
